Allen-Narker R A, Roberts C J, Marshall A J, Jordan S C, Barritt D W, Goodfellow R M
Br J Clin Pharmacol. 1984 Nov;18(5):725-32. doi: 10.1111/j.1365-2125.1984.tb02535.x.
Five hundred and seventy one patients admitted to a coronary care unit with suspected acute myocardial infarction were considered for entry into a double-blind study. Two hundred and eighty-three patients were excluded, mainly because of recent treatment with beta-adrenoceptor blocking agents, life threatening arrhythmias requiring specific treatment and left ventricular failure presenting with hypotension or pulmonary oedema. Two hundred and eighty-eight entered the trial of whom 202 were subsequently confirmed to have had myocardial infarction. The effects of tocainide and disopyramide on ventricular arrhythmias were compared with placebo over the first 48 h period. The three treatments were given by a combination of intravenous infusion and oral administration. The doses used were tocainide 500 mg intravenously over 30 min plus 2800 mg orally over 48 h and disopyramide 150 mg intravenously over 30 min plus 1050 mg orally over 48 h. As judged by counts of ventricular premature beats, tocainide and disopyramide exerted a similar and significant antiarrhythmic effect. The median number of ventricular premature beats over the first 24 h of treatment was 58 on placebo compared with 30 on tocainide (P less than 0.05) and 19 on disopyramide (P less than 0.05). The corresponding figures for the second 24 h were 9, 6 and 2, respectively. There were eight deaths and three episodes of ventricular fibrillation with no significant differences between the three treatment groups. Sustained ventricular tachycardia was observed in one patient in the tocainide group.(ABSTRACT TRUNCATED AT 250 WORDS)
571名因疑似急性心肌梗死入住冠心病监护病房的患者被考虑纳入一项双盲研究。283名患者被排除,主要原因是近期使用了β肾上腺素受体阻滞剂、需要特殊治疗的危及生命的心律失常以及伴有低血压或肺水肿的左心室衰竭。288名患者进入试验,其中202名随后被确诊患有心肌梗死。在最初的48小时内,将妥卡尼和丙吡胺对室性心律失常的作用与安慰剂进行了比较。三种治疗均通过静脉输注和口服联合给药。使用的剂量为妥卡尼30分钟内静脉注射500毫克,48小时内口服2800毫克;丙吡胺30分钟内静脉注射150毫克,48小时内口服1050毫克。根据室性早搏计数判断,妥卡尼和丙吡胺具有相似且显著的抗心律失常作用。治疗的前24小时,安慰剂组室性早搏的中位数为58次,妥卡尼组为30次(P<0.05),丙吡胺组为19次(P<0.05)。第二个24小时的相应数字分别为9次、6次和2次。三个治疗组之间有8例死亡和3次室颤发作,无显著差异。妥卡尼组有1例患者出现持续性室性心动过速。(摘要截短于250字)